Akhil Parlapalli
Analyst
Akhil Parlapalli is an Analyst at CBPartners.
Connect with Akhil Parlapalli
Published Articles
May 26, 2020 | Podcasts
COVID-19 (Pt 3): Testing
The final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist.
April 29, 2020 | Blog
Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?
Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.
April 21, 2020 | Podcasts
CBPartners’ Pharma Take-Away: COVID-19 (Pt 2): Promising Treatments in Development
In Part 2 of the COVID-19 series, healthcare consultant Jared Wolff is again joined by Matthew Rube and Akhil Parlapalli from CBPartners’ New York office to discuss some of the most promising treatments that are currently being put to the test against COVID-19.
March 17, 2020 | Podcasts
CBPartners’ Pharma Take-Away: COVID-19 (Pt 1): Roundtable
In this episode, Jared Wolff is joined by Matthew Rube and Akhil Parlapalli from CBPartners' New York office to discuss some of the topics surrounding the novel coronavirus (COVID-19) pandemic: